IMMX - Immix Biopharma rises 11% after subsidiary Nexcella posts positive data from amyloidosis and multiple myeloma treatment

2023-04-27 09:38:46 ET

• Immix Biopharma's ( NASDAQ: IMMX ) subsidiary Nexcella released positive results from its ongoing Phase 1b/2 NEXICART-1 study on NXC-201, its autologous BCMA-targeted CAR-T cell therapy. to treat relapsed or refractory ( AL ) amyloidosis and multiple myeloma.
• ( IMMX ) is trading 11% higher .
• According to the latest data cutoff, the ongoing trial showed that NXC-201, at the therapeutic dose of 800 million CAR+T cells, generated an overall response rate of 92% in relapsed/refractory multiple myeloma patients who had not been previously treated with BCMA-targeted therapy. Additionally, the therapy resulted in a median progression-free survival of 12.3 months.
• Nexcella plans to submit a BLA for FDA approval in multiple myeloma once 100 patients are treated with NXC-201.
• In the ongoing Phase 1b/2a NEXICART-1 clinical trial, NXC-201 has demonstrated an overall response rate of 100% in the 8 light chain ( AL ) amyloidosis patients treated with the therapy.
• Nexcella plans to submit a BLA for FDA approval in AL amyloidosis once 30-40 patients are treated with NXC-201.
• Press Release

For further details see: